1123 related articles for article (PubMed ID: 19875971)
1. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
2. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
3. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
4. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
5. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
Bénard F; Sterman D; Smith RJ; Kaiser LR; Albelda SM; Alavi A
Chest; 1998 Sep; 114(3):713-22. PubMed ID: 9743156
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
8. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET.
Schaffler GJ; Wolf G; Schoellnast H; Groell R; Maier A; Smolle-Jüttner FM; Woltsche M; Fasching G; Nicoletti R; Aigner RM
Radiology; 2004 Jun; 231(3):858-65. PubMed ID: 15105451
[TBL] [Abstract][Full Text] [Related]
9. Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease.
Kurata S; Ishibashi M; Azuma K; Kaida H; Takamori S; Fujimoto K; Kobayashi M; Hirose Y; Aizawa H; Hayabuchi N
Jpn J Radiol; 2010 Jul; 28(6):446-52. PubMed ID: 20661695
[TBL] [Abstract][Full Text] [Related]
10. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
11. The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion.
Sun Y; Yu H; Ma J; Lu P
PLoS One; 2016; 11(8):e0161764. PubMed ID: 27560933
[TBL] [Abstract][Full Text] [Related]
12. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
13. Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
Tan C; Barrington S; Rankin S; Landau D; Pilling J; Spicer J; Cane P; Lang-Lazdunski L
J Thorac Oncol; 2010 Mar; 5(3):385-8. PubMed ID: 20087231
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up).
Niccoli-Asabella A; Notaristefano A; Rubini D; Altini C; Ferrari C; Merenda N; Fanelli M; Rubini G
Clin Imaging; 2013; 37(6):1098-103. PubMed ID: 23932389
[TBL] [Abstract][Full Text] [Related]
15. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
Carretta A; Landoni C; Melloni G; Ceresoli GL; Compierchio A; Fazio F; Zannini P
Eur J Cardiothorac Surg; 2000 Apr; 17(4):377-83. PubMed ID: 10773558
[TBL] [Abstract][Full Text] [Related]
16. Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
Bille A; Chicklore S; Okiror L; Cook GJ; Spicer J; Landau D; Lang-Lazdunski L
Nucl Med Commun; 2013 Nov; 34(11):1075-83. PubMed ID: 23963351
[TBL] [Abstract][Full Text] [Related]
17. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P
Respiration; 2015; 89(6):558-64. PubMed ID: 25966972
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
Schneider DB; Clary-Macy C; Challa S; Sasse KC; Merrick SH; Hawkins R; Caputo G; Jablons D
J Thorac Cardiovasc Surg; 2000 Jul; 120(1):128-33. PubMed ID: 10884665
[TBL] [Abstract][Full Text] [Related]
19. 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough.
Roca E; Laroumagne S; Vandemoortele T; Berdah S; Dutau H; Maldonado F; Astoul P
Lung Cancer; 2013 Feb; 79(2):187-90. PubMed ID: 23206832
[TBL] [Abstract][Full Text] [Related]
20. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
